Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | LYN | P07948 | 3/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SYK | P43405 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | DDX3X | O00571 | 1/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29377238 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL726190 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1673189 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL8217 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29370699 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1440465 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL5004429 | 0.99 | ABL1 (0.97) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859559 | 0.97 | ABL1 (0.94) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560959-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | disclosed |
| EP-3389712-B1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | NOVARTIS AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-11939397-B2 | ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | NOVARTIS AG (CH) | 2024-03-26 | — | — | US | disclosed |
| EP-4324518-A2 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023242561-A1 | TREATMENT OF TUBERCULOSIS | CHARIOT INNOVATIONS LTD (GB) | 2023-12-21 | — | — | WO | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| WO-2005067963-A1 | USE OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON-ALPHA IN THERAPEUTIC DOSING REGIMENS | INTERMUNE, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005040758-A2 | USE OF PIRFENIDONE IN THERAPEUTIC REGIMENS | INTERMUNE, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1514105-A2 | METHODS OF MODULATING TUBULIN DEACETYLASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005016241-A2 | SYNTHETIC CHEMOKINE RECEPTOR LIGANDS AND METHODS OF USE THEREOF | INTERMUNE, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004110245-A2 | COMBINATION THERAPY FOR CANCER TREATMENT | INTERMUNE, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040028607-A1 | Methods of modulating tubulin deacetylase activity | THE J. DAVID GLADSTONE INSTITUTES | 2004-02-12 | — | — | US | disclosed |
| WO-2003099210-A2 | METHODS OF MODULATING TUBULIN DEACETYLASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003075828-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | ZETIQ TECHNOLOGIES LTD. (IL) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | ABL1 1310/4885BCR 249/4885KIT 2225/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | ABL1 304/4885BCR 15/4885KIT 3468/4885 |
| US-11939397-B2 | ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | ENTPD2, ENTPD1, ENTPD3 | ABL1 3198/4885BCR 2357/4885KIT 3039/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | ABL1 1109/4885BCR 3199/4885KIT 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.